Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DESVENLAFAXINE

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Venlafaxine (Effexor XR): general benefit
  • Vortioxetine (Trintellix): general benefit
  • Bupropion (Wellbutrin XL): limited Use 315, Not a benefit

17 more in the class list below

Apo-Desvenlafaxine · DIN 02466988 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Desvenlafaxine · DIN 02466988 Manufacturer: Apotex Inc.; listing date 2017-12-21 Health Canada: Marketed since 2017-10-20 · brand APO-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95539 · Verify on the e-Formulary ↗ (DIN 02466988)

Source record
DIN 02466988: Apo-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id APX Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466988 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95539
Interchangeable products
Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2026-01-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466988
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desvenlafaxine · DIN 02535106 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02535106 Manufacturer: Sanis Health Inc.; listing date 2023-05-31 Health Canada: Marketed since 2023-05-25 · brand DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 50 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102398 · Verify on the e-Formulary ↗ (DIN 02535106)

Source record
DIN 02535106: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id SAI Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535106 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102398
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2024-11-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535106
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desvenlafaxine · DIN 02554968 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02554968 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-05-30 Health Canada: Marketed since 2025-05-13 · brand DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 50 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104377 · Verify on the e-Formulary ↗ (DIN 02554968)

Source record
DIN 02554968: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id SIV Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554968 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104377
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554968
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Desvenlafaxine · DIN 02495139 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Desvenlafaxine · DIN 02495139 Manufacturer: Jamp Pharma Corporation; listing date 2022-05-31 Health Canada: Marketed since 2022-02-14 · brand JAMP DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98506 · Verify on the e-Formulary ↗ (DIN 02495139)

Source record
DIN 02495139: Jamp Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id JPC Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495139 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98506
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2024-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495139
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pristiq · DIN 02321092 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pristiq · DIN 02321092 Manufacturer: Pfizer Canada Inc.; listing date 2017-12-21 Health Canada: Marketed since 2014-12-06 · brand PRISTIQ · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pristiq: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80650 · Verify on the e-Formulary ↗ (DIN 02321092)

Source record
DIN 02321092: Pristiq Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id PFI Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321092 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80650
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2023-10-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02321092
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Desvenlafaxine · DIN 02538415 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Desvenlafaxine · DIN 02538415 Manufacturer: Sandoz Canada Inc.; listing date 2024-02-29 Health Canada: Marketed since 2024-05-30 · brand SANDOZ DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 50 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102714 · Verify on the e-Formulary ↗ (DIN 02538415)

Source record
DIN 02538415: Sandoz Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538415 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102714
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2026-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538415
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Desvenlafaxine · DIN 02532158 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Desvenlafaxine · DIN 02532158 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-10-31 Health Canada: Marketed since 2024-02-12 · brand TARO-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102121 · Verify on the e-Formulary ↗ (DIN 02532158)

Source record
DIN 02532158: Taro-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id TAR Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02532158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102121
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: active shortage (reported 2026-05-01, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02532158
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Desvenlafaxine · DIN 02458217 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Desvenlafaxine · DIN 02458217 Manufacturer: Teva Canada Limited; listing date 2022-04-29 Health Canada: Marketed since 2022-02-14 · brand TEVA-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94528 · Verify on the e-Formulary ↗ (DIN 02458217)

Source record
DIN 02458217: Teva-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id TEV Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458217 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94528
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02467119 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded
Shortage status: resolved shortage (ended 2026-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458217
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Desvenlafaxine · DIN 02466996 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Desvenlafaxine · DIN 02466996 Manufacturer: Apotex Inc.; listing date 2017-12-21 Health Canada: Marketed since 2017-10-20 · brand APO-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95540 · Verify on the e-Formulary ↗ (DIN 02466996)

Source record
DIN 02466996: Apo-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id APX Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95540
Interchangeable products
Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: resolved shortage (ended 2024-10-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02466996
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desvenlafaxine · DIN 02535114 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02535114 Manufacturer: Sanis Health Inc.; listing date 2023-05-31 Health Canada: Marketed since 2023-05-25 · brand DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102399 · Verify on the e-Formulary ↗ (DIN 02535114)

Source record
DIN 02535114: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id SAI Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535114 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102399
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: resolved shortage (ended 2024-11-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535114
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desvenlafaxine · DIN 02554976 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02554976 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2025-05-30 Health Canada: Marketed since 2025-05-13 · brand DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104378 · Verify on the e-Formulary ↗ (DIN 02554976)

Source record
DIN 02554976: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id SIV Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554976 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104378
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554976
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Desvenlafaxine · DIN 02495147 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Desvenlafaxine · DIN 02495147 Manufacturer: Jamp Pharma Corporation; listing date 2022-05-31 Health Canada: Marketed since 2022-02-14 · brand JAMP DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98510 · Verify on the e-Formulary ↗ (DIN 02495147)

Source record
DIN 02495147: Jamp Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id JPC Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02495147 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98510
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: resolved shortage (ended 2024-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02495147
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pristiq · DIN 02321106 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Pristiq · DIN 02321106 Manufacturer: Pfizer Canada Inc.; listing date 2017-12-21 Health Canada: Marketed since 2014-12-06 · brand PRISTIQ · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Pristiq: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80651 · Verify on the e-Formulary ↗ (DIN 02321106)

Source record
DIN 02321106: Pristiq Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id PFI Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321106 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80651
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: resolved shortage (ended 2023-09-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02321106
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Desvenlafaxine · DIN 02538423 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Desvenlafaxine · DIN 02538423 Manufacturer: Sandoz Canada Inc.; listing date 2024-02-29 Health Canada: Marketed since 2024-05-30 · brand SANDOZ DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE 100 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102715 · Verify on the e-Formulary ↗ (DIN 02538423)

Source record
DIN 02538423: Sandoz Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538423 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102715
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02538423
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Desvenlafaxine · DIN 02532166 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Desvenlafaxine · DIN 02532166 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2023-10-31 Health Canada: Marketed since 2024-02-12 · brand TARO-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102122 · Verify on the e-Formulary ↗ (DIN 02532166)

Source record
DIN 02532166: Taro-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id TAR Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02532166 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102122
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: active shortage (reported 2025-11-03, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02532166
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Desvenlafaxine · DIN 02458225 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Desvenlafaxine · DIN 02458225 Manufacturer: Teva Canada Limited; listing date 2022-04-29 Health Canada: Marketed since 2022-02-14 · brand TEVA-DESVENLAFAXINE · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94529 · Verify on the e-Formulary ↗ (DIN 02458225)

Source record
DIN 02458225: Teva-Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id TEV Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02458225 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94529
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02467127 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02458225
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Desvenlafaxine · DIN 02467119 · 50mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-04-19 · checked 2026-09-02 · What does dormant mean?
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02467119 Manufacturer: Apotex Inc.; listing date 2022-04-29 Health Canada: Dormant since 2025-04-19 · brand APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95551 · Verify on the e-Formulary ↗ (DIN 02467119)

Source record
DIN 02467119: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604130; group id 457; item number 1141; lccId None; manufacturer id APX Source form: ER Tab; strength: 50mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467119 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95551
Interchangeable products
Apo-Desvenlafaxine · DIN 02466988 · not recorded Desvenlafaxine · DIN 02535106 · not recorded Desvenlafaxine · DIN 02554968 · not recorded Jamp Desvenlafaxine · DIN 02495139 · not recorded Pristiq · DIN 02321092 · not recorded Sandoz Desvenlafaxine · DIN 02538415 · not recorded Taro-Desvenlafaxine · DIN 02532158 · not recorded Teva-Desvenlafaxine · DIN 02458217 · not recorded
Shortage status: resolved shortage (ended 2023-06-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-04-19 — choose a marketed DIN from the same-category list.

Desvenlafaxine · DIN 02467127 · 100mg · extended release tablet

Off-Formulary Interchangeable, not an ODB benefitDormant since 2025-03-21 · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desvenlafaxine · DIN 02467127 Manufacturer: Apotex Inc.; listing date 2022-04-29 Health Canada: Dormant since 2025-03-21 · brand APO-DESVENLAFAXINE EXTENDED-RELEASE TABLETS · ATC N06AX23 DESVENLAFAXINE · form Tablet (extended-release) · route Oral · ingredients DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95552 · Verify on the e-Formulary ↗ (DIN 02467127)

Source record
DIN 02467127: Desvenlafaxine Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281604131; group id 457; item number 1142; lccId None; manufacturer id APX Source form: ER Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $2.3409; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467127 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95552
Interchangeable products
Apo-Desvenlafaxine · DIN 02466996 · not recorded Desvenlafaxine · DIN 02535114 · not recorded Desvenlafaxine · DIN 02554976 · not recorded Jamp Desvenlafaxine · DIN 02495147 · not recorded Pristiq · DIN 02321106 · not recorded Sandoz Desvenlafaxine · DIN 02538423 · not recorded Taro-Desvenlafaxine · DIN 02532166 · not recorded Teva-Desvenlafaxine · DIN 02458225 · not recorded
Shortage status: resolved shortage (ended 2024-03-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-03-21 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VENLAFAXINE HCL

· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

BUPROPION HCL

· 12 products · Limited Use, codes 315 (10), Listed, not a benefit (2) · strengths: 150mg, 300mg, 100mg · ER Tab, Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: major depressive disorder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: BREXPIPRAZOLE, VORTIOXETINE HYDROBROMIDE BREXPIPRAZOLE · General benefit • use as an adjunct to antidepressants for the treatment of major depressive disorder (MDD) in adult patients with an inadequate response to prior antidepressant treatments during the current episode (see 14.1 Clinical Trials by Indication, Adjunctive Treatment in Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00074327.PDF; date February 16, 2017; DIN 02461749; fetched 2026-09-10 Product monograph DULOXETINE · Listed, not a benefit (2), General benefit (36) 1 Indications pms-DULOXETINE (Duloxetine Delayed-Release Capsules) is indicated in adults for: • Major Depressive Disorder pms-DULOXETINE is indicated for the symptomatic relief of major depressive disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00084896.PDF; date 2026-05-29; DIN 02429446; fetched 2026-09-10 Product monograph FLUOXETINE HCL · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) 1 INDICATIONS pms-FLUOXETINE (fluoxetine) is indicated in adults for: • Depression: pms-FLUOXETINE is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00076968.PDF; date AUG 30, 2024; DIN 02177579; fetched 2026-09-10 Product monograph VILAZODONE HYDROCHLORIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VIIBRYD (vilazodone hydrochloride tablets) is indicated for the symptomatic relief of Major Depressive Disorder (MDD). PM: https://pdf.hres.ca/dpd_pm/00073801.PDF; date JUL 15, 2015; DIN 02443724; fetched 2026-09-10 Product monograph VORTIOXETINE HYDROBROMIDE · General benefit 1 Indications TRINTELLIX (vortioxetine hydrobromide) is indicated for: • the treatment of major depressive disorder (MDD) in adults. PM: https://pdf.hres.ca/dpd_pm/00085298.PDF; date 2026-07-10; DIN 02432919; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS PRISTIQ (desvenlafaxine succinate) is indicated for: • symptomatic relief of major depressive disorder in adults. The short-term efficacy of PRISTIQ has been demonstrated in placebo-controlled trials of up to 8 weeks. The efficacy of PRISTIQ in maintaining an antidepressant response for up to 26 weeks, following response during 20 weeks of acute, open-label treatment, was demonstrated in a placebo-controlled trial. Physicians who elect to use PRISTIQ for extended periods should periodically re-evaluate the usefulness of the drug for individual patients. 1.1 Pediatrics Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of PRISTIQ in pediatric patients have not been established; therefore, Health Canada has not authorized an indication for pediatric use. Two placebo-controlled studies in 587 pediatric patients 7 to 17 years of age with MDD failed to demonstrate efficacy; neither short term, placebo-controlled study demonstrated statistically or clinically significant differences between PRISTIQ and placebo. See 7 WARNINGS AND PRECAUTIONS, Potential Association with Behavioural and Emotional Changes, I… https://pdf.hres.ca/dpd_pm/00074568.PDF PM date: FEB 04, 2009 Source product: PRISTIQ; DIN 02321092; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Taro-Desvenlafaxine · DIN 02532158 Shortage status: active shortage (reported 2026-05-01, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02532158

Check this DIN again

Taro-Desvenlafaxine · DIN 02532166 Shortage status: active shortage (reported 2025-11-03, estimated to end 2026-09-25, last updated 2026-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02532166

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Apo-Desvenlafaxine, Desvenlafaxine, Jamp Desvenlafaxine, Pristiq, Sandoz Desvenlafaxine, Taro-Desvenlafaxine, Teva-Desvenlafaxine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026